Celyad Oncology SA
XBRU:CYAD

Watchlist Manager
Celyad Oncology SA Logo
Celyad Oncology SA
XBRU:CYAD
Watchlist
Price: 0.682 EUR 1.79% Market Closed
Market Cap: 28.3m EUR
Have any thoughts about
Celyad Oncology SA?
Write Note

EV/OCF
Enterprise Value to OCF

-2.3
Current
-0.6
Median
6.1
Industry
Lower than median
Lower than industry value

Enterprise Value to Operating Cash Flow (EV/OCF) ratio is a valuation multiple that measures the value of a company, debt included, to the operating cash flow it generates.

EV/OCF
-2.3
=
Enterprise Value
22.2m EUR
/
Operating Cash Flow
-9.7m EUR
All Countries
Close
 
BE
Celyad Oncology SA
XBRU:CYAD
Average EV/OCF: 22.1
Negative Multiple: -2.3
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -241 885.9
US
Abbvie Inc
NYSE:ABBV
22.5
US
Amgen Inc
NASDAQ:AMGN
26
US
Gilead Sciences Inc
NASDAQ:GILD
10.9
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Negative Multiple: -116
US
E
Epizyme Inc
F:EPE
Negative Multiple: -465.5
AU
CSL Ltd
ASX:CSL
34.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17
US
S
Seagen Inc
F:SGT
Negative Multiple: -72.8
NL
argenx SE
XBRU:ARGX
Negative Multiple: -133.3

EV/OCF Forward Multiples

Forward EV/OCF multiple is a version of the EV/OCF ratio that uses forecasted operating cash flow for the EV/OCF calculation. 1-Year, 2-Years, and 3-Years forwards use operating cash flow forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/OCF
N/A
2-Years Forward
EV/OCF
N/A
3-Years Forward
EV/OCF
N/A